IL305751A - Synthesis of omecamtiv mecarbil - Google Patents

Synthesis of omecamtiv mecarbil

Info

Publication number
IL305751A
IL305751A IL305751A IL30575123A IL305751A IL 305751 A IL305751 A IL 305751A IL 305751 A IL305751 A IL 305751A IL 30575123 A IL30575123 A IL 30575123A IL 305751 A IL305751 A IL 305751A
Authority
IL
Israel
Prior art keywords
synthesis
omecamtiv mecarbil
mecarbil
omecamtiv
Prior art date
Application number
IL305751A
Other languages
Hebrew (he)
Inventor
Sebastien Caille
James Murray
Kyle Quasdorf
Hannah Nguyen
Elipe Maria Victoria Silva
Ari Elizabeth Ericson
Original Assignee
Amgen Inc
Sebastien Caille
James Murray
Kyle Quasdorf
Hannah Nguyen
Elipe Maria Victoria Silva
Ari Elizabeth Ericson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Sebastien Caille, James Murray, Kyle Quasdorf, Hannah Nguyen, Elipe Maria Victoria Silva, Ari Elizabeth Ericson filed Critical Amgen Inc
Publication of IL305751A publication Critical patent/IL305751A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/08Preparation of nitro compounds by substitution of hydrogen atoms by nitro groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/10Preparation of nitro compounds by substitution of functional groups by nitro groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/12Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/16Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/12Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL305751A 2021-03-10 2022-03-09 Synthesis of omecamtiv mecarbil IL305751A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163159227P 2021-03-10 2021-03-10
PCT/US2022/019573 WO2022192414A2 (en) 2021-03-10 2022-03-09 Synthesis of omecamtiv mecarbil

Publications (1)

Publication Number Publication Date
IL305751A true IL305751A (en) 2023-11-01

Family

ID=80937110

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305751A IL305751A (en) 2021-03-10 2022-03-09 Synthesis of omecamtiv mecarbil

Country Status (13)

Country Link
US (1) US11702380B2 (en)
EP (1) EP4305018A2 (en)
JP (1) JP7843295B2 (en)
KR (1) KR20240006498A (en)
CN (1) CN117157274B (en)
AU (1) AU2022232919A1 (en)
BR (1) BR112023018095A2 (en)
CA (1) CA3212491A1 (en)
CL (1) CL2023002667A1 (en)
IL (1) IL305751A (en)
MX (1) MX2023010558A (en)
TW (1) TW202300479A (en)
WO (1) WO2022192414A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522579T3 (en) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compounds, compositions and methods
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
DK3645002T3 (en) 2017-06-30 2024-12-16 Amgen Inc METHODS FOR TREATING HEART FAILURE WITH CARDIAC SARCOMA ACTIVATORS
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
PT3594199T (en) 2018-07-09 2020-09-04 Amgen Inc Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
MA53226A (en) 2018-08-17 2021-11-24 Amgen Inc SALT AND CRYSTALLINE FORMS OF OMECAMTIV MECARBIL
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
DK4243825T3 (en) 2020-11-12 2025-12-01 Amgen Inc OMECAMTIV MECARBIL FOR THE TREATMENT OF HEART FAILURE IN SELECTED PATIENT GROUPS
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc Synthesis of omecamtiv mecarbil
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS624279A (en) * 1985-06-28 1987-01-10 Mitsubishi Chem Ind Ltd Production of nitrophthalide
JP2002080491A (en) * 2000-09-04 2002-03-19 Japan Science & Technology Corp Novel nucleotide analogues and their production
CN1942461B (en) * 2004-04-14 2011-11-09 默克专利股份有限公司 Dibenzofuran-, dibenzothiophene- and fluorene derivatives
ES2522579T3 (en) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compounds, compositions and methods
JP5044919B2 (en) * 2005-10-07 2012-10-10 Jnc株式会社 Compound having alkyl group in benzene ring, liquid crystal composition containing this compound, and liquid crystal display device containing this liquid crystal composition
ES2419007T3 (en) 2005-12-15 2013-08-19 Cytokinetics, Inc. Certain chemical entities, compositions and procedures
CN101177400A (en) * 2006-11-06 2008-05-14 吕铁环 Method for producing 2-fluorin-3-nitrotoluene
WO2013119751A1 (en) * 2012-02-09 2013-08-15 Boehringer Ingelheim International Gmbh Process for preparing carboxamidine compounds
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
US9895308B2 (en) 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
CN103626791B (en) * 2013-11-26 2016-04-06 大连联化化学有限公司 A kind of method of synthesizing 3-amino-4-fluorobenzoic boric acid
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
MA49506B1 (en) * 2017-06-30 2021-09-30 Amgen Inc Synthesis of omecamtiv mecarbil
DK3645002T3 (en) 2017-06-30 2024-12-16 Amgen Inc METHODS FOR TREATING HEART FAILURE WITH CARDIAC SARCOMA ACTIVATORS
AU2018294254C1 (en) * 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
PT3594199T (en) 2018-07-09 2020-09-04 Amgen Inc Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
EP3820851A1 (en) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
MA53226A (en) 2018-08-17 2021-11-24 Amgen Inc SALT AND CRYSTALLINE FORMS OF OMECAMTIV MECARBIL
JP2020075876A (en) * 2018-11-07 2020-05-21 田岡化学工業株式会社 9-silafluorene compound having nitro group and production method thereof
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
CN114929671B (en) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 Eutectic of compound I dihydrochloride and preparation method and application thereof
US20230090391A1 (en) 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
DK4243825T3 (en) 2020-11-12 2025-12-01 Amgen Inc OMECAMTIV MECARBIL FOR THE TREATMENT OF HEART FAILURE IN SELECTED PATIENT GROUPS
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc Synthesis of omecamtiv mecarbil

Also Published As

Publication number Publication date
CA3212491A1 (en) 2022-09-15
WO2022192414A3 (en) 2022-10-27
EP4305018A2 (en) 2024-01-17
MX2023010558A (en) 2023-11-24
US11702380B2 (en) 2023-07-18
TW202300479A (en) 2023-01-01
CL2023002667A1 (en) 2024-02-02
CN117157274B (en) 2026-02-10
CN117157274A (en) 2023-12-01
JP7843295B2 (en) 2026-04-09
US20220298099A1 (en) 2022-09-22
JP2024509797A (en) 2024-03-05
AU2022232919A1 (en) 2023-10-19
KR20240006498A (en) 2024-01-15
BR112023018095A2 (en) 2023-12-12
WO2022192414A2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
IL305751A (en) Synthesis of omecamtiv mecarbil
HUE061482T2 (en) Method of synthesis
IL311128A (en) Synthesis of nirogacestat
SMT202100472T1 (en) Synthesis of omecamtiv mecarbil
IL300309B2 (en) Synthesis of quinazoline compounds
GB202103774D0 (en) Detectiion of Ransomware
KR102423280B9 (en) Sot-mram area-optimized design of sot-mram
GB202411655D0 (en) Application of circHIF1a
GB201903055D0 (en) Method of oligonucleaotide synthesis
GB2616849B (en) Improved synthesis
IL307826A (en) Processes for the synthesis of valbenazine
IL308487A (en) Novel synthesis of cholesterol
GB202008101D0 (en) Synthesis of nanoparticles
GB202118156D0 (en) Methods of synthesis
GB202118099D0 (en) Methods of synthesis
GB202118005D0 (en) Methods of synthesis
EP3983423A4 (en) Synthesis of 3-azido-3-deoxy-d-galactopyranose
IL325821A (en) Methods of synthesis
IL326732A (en) Synthesis of lanifibranor intermediate
GB202211474D0 (en) Methods of synthesis
PL3966214T3 (en) Synthesis of coelenterazine
GB201804905D0 (en) Cataltic synthesis of biarylic compounds
GB202111264D0 (en) Synthesis of heterocycles
HK40112975A (en) Synthesis of nirogacestat
GB202017799D0 (en) Method of synthesis